Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/CHUGAI-PHARMACEUTICAL-CO--6491165/news/Chugai-Pharmaceutical-Enspryng-Satralizumab-von-Chugai-erhalt-FDA-Zulassung-fur-Neuromyelitis-31134010/?utm_source=whatsapp&utm_medium=social&utm_campaign=share